SEC Form 4 · accession 0001209191-17-046030
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, CFO & COO
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 8:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 19, 2017 | M | 25,500 | $96.87 | A | 151,738 | D | |
| Common Stock | Jul 19, 2017 | M | 10,775 | $91.05 | A | 162,513 | D | |
| Common Stock | Jul 19, 2017 | M | 55,250 | $77.31 | A | 217,763 | D | |
| Common Stock | Jul 19, 2017 | M | 31,875 | $83.36 | A | 249,638 | D | |
| Common Stock | Jul 19, 2017 | S | 123,400 | $161.00 | D | 126,238 | D | |
| Common StockF2,F3 | Jul 21, 2017 | S | 400 | $157.56 | D | 125,838 | D | |
| Common StockF3,F4 | Jul 21, 2017 | S | 1,829 | $158.62 | D | 124,009 | D | |
| Common StockF3,F5 | Jul 21, 2017 | S | 815 | $159.61 | D | 123,194 | D | |
| Common StockF3,F6 | Jul 21, 2017 | S | 2,000 | $161.01 | D | 121,194 | D | |
| Common StockF3,F7 | Jul 21, 2017 | S | 5,106 | $161.71 | D | 116,088 | D | |
| Common StockF3,F8 | Jul 21, 2017 | S | 200 | $162.40 | D | 115,888 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401k |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F9 | $96.87 | Jul 19, 2017 | M | 25,500 | D | — | Jul 14, 2024 | Common Stock | 25,500 | 8,500 | D |
| Stock Option (Right to Buy)F10 | $91.05 | Jul 19, 2017 | M | 10,775 | D | — | Feb 1, 2026 | Common Stock | 10,775 | 23,707 | D |
| Stock Option (Right to Buy)F11 | $77.31 | Jul 19, 2017 | M | 55,250 | D | — | Feb 4, 2024 | Common Stock | 55,250 | 12,750 | D |
| Stock Option (Right to Buy)F12 | $83.36 | Jul 19, 2017 | M | 31,875 | D | — | Jul 29, 2023 | Common Stock | 31,875 | 2,125 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- F10The option vests in 16 quarterly installments from 02/02/2016.
- F11The option vests in 16 quarterly installments from 02/05/2014.
- F12The option vests in 16 quarterly installments from 07/30/2013.
- F2Open market sales reported on this line occurred at a weighted average price of $157.56 (range $156.99 to $157.90).
- F3Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $158.62 (range $158.11 to $159.09).
- F5Open market sales reported on this line occurred at a weighted average price of $159.61 (range $159.16 to $159.90).
- F6Open market sales reported on this line occurred at a weighted average price of $161.01 (range $160.28 to $161.24).
- F7Open market sales reported on this line occurred at a weighted average price of $161.71 (range $161.28 to $162.20).
- F8Open market sales reported on this line occurred at a weighted average price of $162.40 (range $162.39 to $162.40).
- F9The option vests in 16 quarterly installments from 7/15/2014.